Xtant Medical Holdings

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoSTX, Certex Spinal Fixation System, Axle Interspinous Fusion System, and Calix. Thecompany was founded in 2006 and is headquartered in Belgrade, MT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xtant Medical Holdings reports robust Q1 growth and raises guidance

Xtant Medical Holdings delivered strong revenue growth in Q1 2024, with a focus on strategic initiatives for future expansion and market penetration.
While facing challenges in supply chain and product cannibalization, the company's emphasis on new products and acquisitions bodes well for long-term growth.
With an increased revenue guidance for 2024 and a positive adjusted EBITDA, Xtant is poised for accelerated organic growth and improved financial performance.

Xtant Medical Holdings reports robust Q2 growth and strategic focus

Xtant Medical Holdings is on track to achieve full-year revenue guidance of $116 million to $120 million.
The company's focus on new products, acquisitions, and operational efficiency bodes well for long-term growth.
Despite challenges in organic growth and net loss, Xtant is strategically positioned for sustainable expansion.

Xtant Medical Holdings reports solid Q3 growth amidst product challenges

Xtant Medical Holdings showed growth in Q3 despite challenges with product delays.
The company is focused on profitability, self-sustainability, and doubling in size by 2024.
Strategic moves like bringing manufacturing in-house and new product releases position Xtant for future growth.
Anticipates revenue growth, margin improvement, and aims for EBITDA positivity in Q4.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoSTX, Certex Spinal Fixation System, Axle Interspinous Fusion System, and Calix. The company was founded in 2006 and is headquartered in Belgrade, MT.

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Brett Maas - IR Sean Browne - President and CEO Scott Neils - CFO Conference Call Participants Operator Welcome to the Xtant Medical Holdings, Inc. Third Quarter 2024 Conference Call. At this time all participants are in a listen only mode.

Xtant Medical Holdings, Inc. (XTNT) Q3 2024 Earnings Conference Call Transcript

Third Quarter Revenue Growth of 12% Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 Million Representing Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Revenue of $27.9 million, up 12%, compared to the prior year quarter; year to date revenue of $85.8 million, up 36% compared to prior year period Gross margin of 58.4% compared to 61.3% for the prior year quarter Net loss of $5.0 million compared to net income of $9.2 million in the prior year quarter which included a $11.0 million bargain purchase gain related to the acquisition of Surgalign Holdings Adjusted EBITDA of $(196,000) compared to $440,000 in the prior year quarter Recent Business Highlights Launched OsteoVive+, a moldable, viable bone matrix for use in a variety of grafting procedures Launched Cortera Posterior Fixation System, a comprehensive solution designed to streamline thoracolumbar fixation surgeries Signed a license agreement for Q-Codes and corresponding SimpliMax Dual Layer Amniotic Membrane, which provides for a minimum of $5.25 million in licensing and royalty fees Completed $5.0 million private placement on August 9, 2024 Sean Browne, President and CEO of Xtant Medical, stated, "During the third quarter, we expanded our market opportunities with the launch of two new products, OsteoVive+ (stem cells) and Cortera Posterior Fixation System.

Xtant Medical Reports Third Quarter 2024 Financial Results

BELGRADE, MT / ACCESSWIRE / November 11, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced announced that Sean Browne, CEO and Scott Neils, CFO will be attending the following upcoming conference: Event: 15th Annual Craig-Hallum Alpha Select Conference Date: November 19, 2024Location: Sheraton NY Times Square Hotel, New York, NYFormat: 1x1 Meetings For more information, please visit: https://www.meetmax.com/sched/event_110237/conference_home.html?bank_access=0&event_id=110237 About Xtant Medical Holdings, Inc. Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures.

Xtant Medical to Attend the 15th Annual Craig-Hallum Alpha Select Conference

BELGRADE, MT / ACCESSWIRE / November 7, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2024, after the close of the financial markets on Tuesday, November 12, 2024. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Tuesday, November 12, 2024 at 4:30 PM ET to review results.

Xtant Medical to Issue Third Quarter 2024 Financial Results on November 12, 2024

New System Enhances Surgical Efficiency and Provides Versatile Solutions for Complex Spine Procedures BELGRADE, MT / ACCESSWIRE / September 23, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leading global medical technology company focused on the treatment of spinal disorders, is excited to announce the launch of the Cortera Posterior Fixation System, a comprehensive solution designed to streamline thoracolumbar fixation surgeries. Now available to surgeons across the United States through Xtant's commercial channels.

Xtant Medical Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System

New Cellular Bone Matrix Designed with Cohesive and Moldable Handling Characteristics BELGRADE, MT / ACCESSWIRE / September 18, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has launched a new addition to its robust product portfolio, OsteoVive Plus, a moldable, viable bone matrix that can be used in a variety of grafting procedures. The graft is now available, to the company's nationwide distribution network of independent agents as well as original equipment manufacturer relationships.

Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q2 2024 Earnings Conference Call August 9, 2024 9:00 AM ET Company Participants Brett Maas - IR Sean Browne - President and CEO Scott Neils - CFO Conference Call Participants Ryan Zimmerman - BTIG Chase Knickerbocker - Craig-Hallum Capital Operator Welcome to the Xtant Medical Holdings, Inc. Second Quarter 2024 Conference Call. [Operator Instructions] I would now like to turn the call over to your host, Brett Maas, IR.

Xtant Medical Holdings, Inc. (XTNT) Q2 2024 Earnings Call Transcript

BELGRADE, MT / ACCESSWIRE / August 9, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of its previously announced $5.0 million private placement with an existing institutional investor. The Company sold 7,812,500 shares of common stock at a purchase price of $0.64 per share.

Xtant Medical Announces Closing of $5.0 Million Private Placement

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a securities purchase agreement with an existing institutional investor to sell shares of its common stock in a private placement. The Company agreed to issue an aggregate of 7,812,500 shares of common stock at a purchase price of $0.64 per share, resulting in gross proceeds of $5.0 million.

Xtant Medical Announces $5.0 Million Private Placement

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2024, after the close of the financial markets on Thursday, August 8, 2024. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Friday, August 9, 2024, at 9:00 AM ET to review results.

Xtant Medical to Host Second Quarter 2024 Financial Results Earnings Conference call on August 9, 2024

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Revenue of $29.9 million, up 48%, compared to the prior year quarter Gross margin of 62.1%, up 50 basis points, compared to the prior year quarter Net loss of $3.9 million compared to $2.2 million in the year ago quarter Positive Adjusted EBITDA; Adjusted EBITDA of $0.5 million compared to $0.1 million in the prior year quarter Recent Business Highlights Recently launched two new amniotic membrane allografts products, SimpliGraft™ and SimpliMax™; while Cortera™ reached record sales and users for the second quarter Signed 15 new distributors in the second quarter Awarded 20 IDN contracts in the second quarter Entered into a $5.0 million private placement on August 7, 2024 Sean Browne, President and CEO of Xtant Medical, stated, "Our second quarter financial results illustrate the positive momentum that is building as we head into the second half of 2024.

Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48%

BELGRADE, MT / ACCESSWIRE / July 25, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will attend the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase being held August 13-15, 2024 at the InterContinental Boston, an IHG Hotel. Sean Browne, President and Chief Executive Officer will present on Wednesday, August 14th at 11:00 a.m.

Xtant Medical to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q1 2024 Results Conference Call May 15, 2024 4:30 PM ET Company Participants Brett Maas - Managing Partner, Hayden IR Sean Browne - President and Chief Executive Officer Scott Neils - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Chase Knickerbocker - Craig-Hallum Operator Greetings. Welcome to the Xtant Medical Holdings, Inc. First Quarter 2024 Conference Call.

Xtant Medical Holdings, Inc. (XTNT) Q1 2024 Earnings Call Transcript

Expects Revenue for Full Year 2024 of $116 Million to $120 Million BELGRADE, MT / ACCESSWIRE / May 15, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue of $27.9 million, up 55%, compared to the prior year quarter Gross margin of 62.1%, up 340 basis points, compared to the prior year quarter Net loss of $4.4 million compared to $2.1 million in the year ago quarter Positive Adjusted EBITDA; Adjusted EBITDA of $0.1 million compared to an Adjusted EBITDA loss of $0.3 million in the prior year quarter Recent Business Highlights Launched two amniotic membrane allografts, SimpliGraft™ and SimpliMax™ Amended its Term Credit and Revolving Credit Agreements to provide additional working capital Sean Browne, President and CEO of Xtant Medical, stated, "In the first quarter of 2024, we delivered strong revenue growth of 55% and positive Adjusted EBITDA, despite continued near-term supply chain challenges for our biologics and spinal hardware product families.

Xtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue Guidance

BELGRADE, MO / ACCESSWIRE / May 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the first quarter ended March 31, 2024, after the close of the financial markets on Wednesday, May 15, 2024. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Wednesday, May 15 at 4:30 PM ET to review results.

Xtant Medical to Issue First Quarter 2024 Financial Results on May 15, 2024

BELGRADE, Mont., April 30, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of two amniotic membrane allografts, SimpliGraft™ and SimpliMax™.

Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds

Xtant Medical Holdings Inc. (XTNT) Q4 2023 Earnings Call Transcript

Establishes Full Year 2024 Revenue Guidance of $112 Million - $116 Million BELGRADE, Mont., April 01, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2023.

Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million

BELGRADE, Mont., March 21, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2023, before the open of the financial markets on Monday, April 1, 2024.

Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024

BELGRADE, Mont., March 07, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company's revolving credit agreement with MidCap Financial Trust (“MidCap”) was amended to increase the commitment from $8.0 million to $17.0 million. The Company's term loan was also amended to provide for an additional $10.0 million tranche, to be made available for acquisitions at MidCap's discretion. The maturity dates of Xtant's revolving credit facility and term loan were extended to March 1, 2029 and minimum net product revenue requirements specified in the agreements were reset and minimum Adjusted EBITDA requirements were removed. Additionally, the applicable margin used to determine the per annum interest rate of the term loan was reduced from 7.00% to 6.50%.

Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial

BELGRADE, Mont., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, Chief Executive Officer, will present at the TD Cowen 44th Annual Healthcare Conference, to be held on Monday, March 4, 2024 at 12:50 p.m. Eastern Time in Boston.

Xtant Medical to Present at the TD Cowen 44th Annual Healthcare Conference

BELGRADE, Mont., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that management will participate in two upcoming investor conferences:

Xtant Medical to Participate in Upcoming Investor Conferences

BELGRADE, Mont., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2023.

Xtant Medical Announces Record Third Quarter Revenue of $25 Million

Expands Xtant's Manufacturing Capabilities and Capacity to Drive Growth BELGRADE, Mont., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has acquired the nanOss production operations from RTI Surgical, Inc., a leading CDMO in regenerative medicine.

Xtant Medical Announces Acquisition of nanOss Production Operations from RTI Surgical

BELGRADE, Mont., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it will exhibit its suite of orthobiologics and spinal fixation products at the North American Spine Society (NASS) 2023 Annual Meeting, which will be held October 18-21 at the Los Angeles Convention Center in Los Angeles, CA.

News for Xtant Medical Holdings Stock (XTNT)